Inflammatory Bowel Disease Market Analysis, Size, Share & Growth Forecast 2026–2034

Treat-to-Target IBD Endoscopic Remission and Mucosal Healing Goal Replacing Clinical Symptom Control as the Primary Treatment Endpoint Has Changed the IBD Management Standard From the Patient-Reported Outcome to the Objective Endoscopic Assessment That Biologic and Targeted Therapy Now Requires.The CALM trial in Crohn disease demonstrated that treat-to-target monitoring using calprotectin and CRP combined with clinical assessment and mandatory therapy optimisation when targets are not met achieves 46% endoscopic remission at 48 weeks versus 30% for symptom-only treatment, establishing the most impactful non-pharmacological advance in CD management through systematic protocol adoption. The STRIDE-II consensus from IOIBD defining composite clinical, biomarker, and endoscopic targets for IBD management has provided the operational framework for tight control implementation that the CALM and REACT trials validated in randomised settings. Tight control strategy implementation requires institutional investment in faecal calprotectin testing infrastructure, scheduled endoscopy with systematic reporting of MES and SES-CD scores, and electronic medical record integration of disease activity calculators that enable protocol-driven therapy adjustment at each patient visit.

IBD Biologic Selection Algorithm Using Disease Severity, Prior Biologic Failure, Fistula, Extraintestinal Manifestations, and Route Preference Navigating Anti-TNF, Anti-Integrin, Anti-IL-23, JAK Inhibitor, and S1P Modulator Classes Has Established the Multi-Mechanism Sequential Treatment Pathway.Celltrion's Remsima, Pfizer's Inflectra, and Sandoz Hyrimoz have collectively achieved 85-90% infliximab biosimilar market share in Norway, Denmark, and Netherlands through mandatory non-medical switching programmes that require prescribers to switch stable patients to biosimilar unless clinical contraindication is documented. The NOR-SWITCH IBD data demonstrating non-inferior disease control after infliximab to biosimilar switching in 481 patients provides the evidence basis for mandatory switching policies that European health technology assessment bodies have endorsed in cost-effectiveness analyses. The infliximab biosimilar market success is informing the regulatory strategy for adalimumab biosimilar adoption in IBD markets, where interchangeability designations and non-medical switching programme implementation are expected to achieve similar biosimilar uptake rates as the infliximab switching experience.

Anti-TNF Biosimilar CT-P13 and Adalimumab Biosimilars 30 to 50 Percent IBD Formulary Market Share Has Reduced Anti-TNF Treatment Cost and Enabled Earlier Biologic Access for the Moderate-to-Severe IBD Patient Whose Anti-TNF Treatment Had Been Restricted by Branded Originator Cost.Crohn's and Colitis Foundation's IBD-PRO application and Medidata's remote monitoring platform are enabling daily symptom logging that provides dense time-series data on patient-reported disease activity between the quarterly clinic visits where clinical assessment has historically occurred. The Harvey-Bradshaw Index and partial Mayo Score computed from daily patient-reported stool frequency and bleeding data provide continuous disease activity tracking that alerts clinicians to disease worsening before the next scheduled appointment, enabling proactive therapy adjustment that reduces the hospitalisation rates from unrecognised flare escalation. Regulatory acceptance of patient-reported outcome measures as endpoints in IBD drug trials requires validation against endoscopic endpoints in standardised populations, and FDA has issued PRO guidance for IBD that defines acceptable questionnaire items and responder definitions for both clinical development and real-world monitoring applications.

For related market intelligence, see the Crohn Disease Market.